Sign in

    Robin Garner

    former Senior Research Analyst at Craig-Hallum

    Robin T. Garner is a former Senior Research Analyst at Craig-Hallum Capital Group, specializing in coverage of the healthcare and life sciences sectors. During her tenure, she published research on companies including Processa Pharmaceuticals, drawing on earlier experience at Aisling Capital, LifeSci Capital, Merrill Lynch, and serving as Head of Investor Relations at Repare Therapeutics. Garner began her investment career after earning a B.S. from Yale University in 2006 and held analyst roles at several leading financial firms from 2010 to 2022. She is recognized for her analytical expertise in healthcare, though specific performance metrics, TipRanks rankings, or FINRA credentials are not publicly documented.

    Robin Garner's questions to Processa Pharmaceuticals (PCSA) leadership

    Robin Garner's questions to Processa Pharmaceuticals (PCSA) leadership • Q1 2022

    Question

    Robin Garner of Craig-Hallum inquired about the development strategy for PCS3117, the expected details of the mid-year data for next-generation capecitabine, and the effectiveness of recent efforts to boost enrollment for the PCS499 trial.

    Answer

    CEO Dr. David Young explained that for PCS3117, the company is developing roadmaps to identify the regulatory path with the highest probability of approval in the shortest time. For next-gen capecitabine, he stated the mid-year data will focus on increased potency and reduced side-effect-causing metabolites to define a go-forward dosage regimen. Regarding PCS499, Dr. Young confirmed that expanded patient outreach and a new pre-screening process are beginning to yield positive results after COVID-related delays.

    Ask Fintool Equity Research AI